The stock last traded at $133.56 a tad higher than the 50 day moving average of $121.46 and which is just over the 200 day moving average of $120.59. The 50 day moving average moved up $12.10 and the 200 day average went up $12.97 or +10.75%. (NASDAQ:CELG) shares saw light trading volume with 2,346K shares changing hands by the end of trading on Thursday. Volume was down 36.64% under the stocks average daily volume.
Short traders are more bearish on Celgene Corporation of late if you take a look at the rise in short interest. The company realized a rise in short interest of 5.71% between June 15, 2017 and May 31, 2017. Short shares increased 541,225 over that period. With short interest at 10,022,677 and short average daily volume at 3,694,442, days to cover is 2.7 and the percentage of shorted shares is 0.01% as of May 31.
Celgene Corporation (NASDAQ:CELG) has been the object of insider selling activity recently. Director Gilla Kaplan sold 14,033 shares at an average price of $123.83 on March 30th. Kaplan now owns $9,053,087 of stock per an SEC filing yesterday. See remarks Rupert Vessey sold 2,500 shares at an average price of $123.18 on Tue the 22nd. That brings the See remarks’s holdings to $141,657 as reported to the SEC.
Michael F. Pehl, See remarks sold $2,670,277 worth of shares at an average price of $121.09 on Thu the 10th. That brings Pehl’s holdings to $0 as recorded in a recent Form 4 SEC filing.
Here are a few additional firms who have increased or decreased their stake in (CELG). Fisher Asset Management, LLC grew its stake by buying 62,060 shares an increase of 30.7% from 03/31/2017 to 06/30/2017. Fisher Asset Management, LLC owns 263,929 shares with a value of $34,276,000. The total value of its holdings increased 36.5%. Gateway Investment Advisers LLC augmented its ownership by buying 36,252 shares an increase of 7.4% in the quarter. Gateway Investment Advisers LLC now controls 524,439 shares valued at $68,109,000. The value of the position overall is up by 12.1%.
Pennsylvania Trust Co expanded its holdings by buying 20,508 shares an increase of 39.3%. Pennsylvania Trust Co claims 72,636 shares worth $9,433,000. The total value of its holdings increased 45.4%. As of the end of the quarter Cullinan Associates Inc had bought 2,900 shares growing its holdings by 4.7%. The value of the investment in CELG increased from $7,109,000 to $8,353,000 increasing 17.5% quarter over quarter.
On June 30 the company was downgraded from “Neutral” to “Neutral” in a report issued by BTIG Research. On June 16, 2017 the stock rating was changed to a “Outperform” according to a Leerink Swann report which was a boost from the previous “Market Perform” rating.
On November 29 analysts at Oppenheimer started covering the stock giving it an initial rating of “Outperform”. On November 9 the company was set at “Hold” by Standpoint Research down from the previous “Buy” rating.
Mizuho started coverage setting a rating of “Buy”. October 5 investment analysts at Jefferies left the stock rating at “Buy” and lowered the price target from $137.00 to $134.00.
The company is now up by 0.99 percent from yesterday’s close. The most current P/E ratio is 50.15 and market capitalization is 104.29B. As of the last earnings report the EPS was $2.66 and is expected to be $7.28 for the current year with 780,824,000 shares currently outstanding. Next quarter’s EPS is estimated at $1.88 and the next full year EPS is anticipated to be $8.78.
Celgene Corporation, launched on April 17, 1986, is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is involved in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Business’s commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier..